Kamada Ltd. (KMDA)

Market Cap	415.95M
Revenue (ttm)	174.79M
Net Income (ttm)	20.44M
Shares Out	57.68M
EPS (ttm)	0.35
PE Ratio	20.35
Forward PE	20.60
Dividend	$0.20 (2.86%)
Ex-Dividend Date	Mar 17, 2025

Volume	61,656
Open	6.88
Previous Close	7.08
Day's Range	6.86 - 7.06
52-Week Range	5.54 - 9.16
Beta	0.14
Analysts	Strong Buy
Price Target	13.00 (+85.98%)
Earnings Date	Nov 10, 2025

About KMDA

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 420
• Stock Exchange: NASDAQ
• Ticker Symbol: KMDA
• Website: https://www.kamada.com

Financial Performance

In 2024, Kamada's revenue was $160.95 million, an increase of 12.93% compared to the previous year's $142.52 million. Earnings were $14.46 million, an increase of 74.58%.

Analyst Summary

According to 2 analysts, the average rating for KMDA stock is "Strong Buy." The 12-month stock price target is $13.0, which is an increase of 85.98% from the latest price.

Price Target

$13.0

(85.98% upside)

Analyst Consensus: Strong Buy